EU approves Danish aid vaccine research

The European Commission has approved a €108 million Danish aid measure to support coronavirus-related research and development (R&D) activities of Bavarian Nordic, a company active in the vaccine development and manufacturing industry. The scheme was approved under the State aid Temporary Framework.

Executive Vice-President Margrethe Vestager, in charge of competition policy, said, “This €108 million Danish aid measure will contribute to much needed research and development activities to respond to the coronavirus outbreak.

“We continue working in close cooperation with Member States to find workable solutions to mitigate the economic impact of the coronavirus outbreak, in line with EU rules,” she added on August 23.

The Danish aid measure

Denmark notified to the Commission under the Temporary Framework a €108 million aid measure to support coronavirus-related R&D activities of Bavarian Nordic, a large company active in the vaccine development and manufacturing industry in Denmark and Germany. The public support will take the form of a repayable advance.

The aim of the measure is to support the development of a novel coronavirus vaccine, developed by AdaptVac and licensed to Bavarian Nordic. The candidate vaccine is currently undergoing phase II clinical trials. The aid will support the next development steps, namely the phase III trial to confirm safety and demonstrate efficacy, the experimental development of the necessary production processes, and the works related to the required regulatory authorisations.

Thank you for taking the time to read this article, please remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and follow us on Facebook and Instagram.